The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...
Medpage Today on MSN5mon
Novel Monoclonal Antibody Protects Infants Against RSVThe investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and prevented ...
Hosted on MSN3mon
Merck's BLA for RSV Antibody Clesrovimab Gets FDA AcceptanceIf approved, clesrovimab can help address the burden of RSV disease in time for the 2025-26 RSV season. Year to date, shares of Merck have declined 8.3% against the industry’s rise of 5.3% ...
MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-growing ...
Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV) prophylaxis, sebetralstat for hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback